RESEARCH AND EDUCATION DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
AHK-CU is a copper-binding tripeptide investigated in laboratory hair-follicle research. This overview explains the experimental findings, distinguishes them from clinical evidence, and separates AHK-CU from the related copper peptide GHK-CU.
WHAT IS AHK-CU?
AHK-CU combines the amino acids alanine, histidine, and lysine with copper. It is a peptide–metal complex. [1]
WHAT DID THE HAIR-FOLLICLE STUDY FIND?
In 2007, Pyo and colleagues studied isolated human hair follicles and cultured dermal papilla cells. They reported increased follicle elongation and a higher cell-assay signal interpreted as proliferation. The assay measured metabolic activity rather than directly counting cells. [1]
The researchers also observed changes in proteins associated with programmed cell death. However, the reduction in cells classified as undergoing that process was not statistically significant. This limits how confidently the results can support a claim that AHK-CU prevents cell death. [1]
HOW IS AHK-CU DIFFERENT FROM GHK-CU?
GHK-CU contains glycine, histidine, and lysine, whereas AHK-CU begins with alanine. These are distinct compounds, and their research should be evaluated separately. [1,2]
For example, a 1988 study by Maquart and colleagues reported increased collagen synthesis in fibroblast cultures exposed to GHK-CU. That experiment provides background on copper-peptide research, but it does not establish the same effect for AHK-CU. [2]
A shared chemical feature is not enough to make two compounds interchangeable. When reviewing a scientific claim, the compound named in the methods should match the compound being discussed.
HOW MUCH EVIDENCE COMES FROM HUMAN STUDIES?
The focused search for this article did not identify a controlled clinical trial establishing AHK-CU alone as a hair-loss treatment.
Human tissue research and clinical research answer different questions. Studying donated tissue outside the body can help investigate biological mechanisms. Establishing a benefit in people requires appropriately designed clinical studies that measure relevant outcomes and adverse effects.
WHAT WOULD STRENGTHEN THE EVIDENCE?
Useful next steps would include independent replication, clearly characterized research materials, and experiments that distinguish changes in metabolic activity from changes in cell number. Comparisons should use matched conditions and assess both favorable and unfavorable results.
Claims about finished products require additional evidence. A laboratory finding does not establish that a particular formulation remains stable, delivers the compound to its intended location, or produces a meaningful outcome. Those questions require testing of the actual formulation.
WHAT REMAINS UNCERTAIN?
This review does not establish an effective human exposure, long-term safety profile, or predictable cosmetic outcome for AHK-CU. It also does not establish superiority over other copper peptides.
For research interpretation, the central distinction is between an observed laboratory response and a validated application. The cited publications should be read as evidence about their specific experiments, not as validation of products sold on this website.
REFERENCES
[1] Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research. 2007;30(7):834–839.
https://doi.org/10.1007/BF02978833
[2] Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 1988;238(2):343–346. GHK-CU study; included for comparison, not as direct AHK-CU evidence.
https://doi.org/10.1016/0014-5793(88)80509-X